Related Experiment Video

Updated: Jun 9, 2025

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.2K

Safety and Effectiveness of Mavacamten Use in Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and

Tuqa Y Alharbi1, Hadel A Alnadawi1, Ghadah M Almutairi1

  • 1College of Medicine, Qassim University, Qassim, SAU.

Cureus
|October 31, 2024
PubMed

Insights

Mavacamten significantly reduces left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy (HOCM) patients. This cardiac myosin inhibitor shows promise for improving cardiac remodeling and stress indicators, suggesting a potential new treatment approach.

Area of Science:

  • Cardiology
  • Pharmacology
  • Genetics

Background:

  • Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiac condition characterized by left ventricular hypertrophy and outflow tract obstruction.
  • Current treatments for HOCM focus on symptom management, with limited options for addressing the underlying pathophysiology.
  • Mavacamten, a novel cardiac myosin inhibitor, presents a potential therapeutic strategy for HOCM.

Purpose of the Study:

  • To evaluate the efficacy and safety of mavacamten in patients diagnosed with hypertrophic obstructive cardiomyopathy (HOCM).
  • To assess the impact of mavacamten on left ventricular outflow tract (LVOT) gradients, cardiac remodeling, and cardiac stress markers.
  • To synthesize findings from randomized controlled trials (RCTs) comparing mavacamten to placebo in HOCM patients.

Main Methods:

  • A systematic literature search was conducted in PubMed and Cochrane Central Register of Controlled Trials.
  • Two randomized controlled trials (RCTs) involving 332 HOCM patients were included in the meta-analysis.
  • Random effects models were employed to analyze changes in LVOT gradients, left atrial volume index (LAVI), left ventricular mass index (LVMI), and NT-proBNP levels.

Main Results:

  • Mavacamten significantly reduced both Valsalva maneuver and resting left ventricular outflow tract (LVOT) gradients compared to placebo.
  • Significant improvements were observed in left atrial volume index (LAVI) and NT-proBNP levels, indicating reduced cardiac stress.
  • A trend towards reduction in left ventricular mass index (LVMI) was noted, alongside a favorable safety profile with few adverse events.

Conclusions:

  • Mavacamten demonstrates significant efficacy in reducing LVOT obstruction and improving cardiac remodeling and stress indicators in HOCM patients.
  • The drug exhibits a favorable short-term safety profile, supporting its potential as a therapeutic option for HOCM.
  • Further long-term studies are warranted to confirm the sustained effectiveness and safety of mavacamten in managing HOCM.

Keywords:
cardiac myosin inhibitorcardiac remodelingh.o.c.ml.v.o.t gradientmavacamten

More Related Videos

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.4K
Minimally Invasive Transverse Aortic Constriction in Mice07:40

Minimally Invasive Transverse Aortic Constriction in Mice

Published on: March 14, 2017

20.4K

Related Concept Videos

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
3
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
5
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
4
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
525